Bulk Pharmaceutical API Sources for hexaminolevulinate hydrochloride

Bulk Pharmaceutical API Sources for hexaminolevulinate hydrochloride

Vendor	Vendor Homepage	Vendor Sku	API Url
Biosynth		A-6140
NovoSeek		6433082
ABI Chem		AC1O5FJ4
ChemMol		49420573
Anward		ANW-58882
Chembase.cn		78469
ChemTik		CTK8B7894

Hexaminolevulinate Hydrochloride API Sourcing: A Global Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of bulk active pharmaceutical ingredient (API) suppliers for hexaminolevulinate hydrochloride, a key component in photodynamic therapy treatments. The analysis focuses on identifying key manufacturers, their production capacities, regulatory standing, and the implications for supply chain stability and cost.

What is Hexaminolevulinate Hydrochloride?

Hexaminolevulinate hydrochloride, also known as 5-aminolevulinic acid hydrochloride (5-ALA HCl), is a precursor molecule that, when administered to the body, is preferentially taken up by rapidly dividing cells, such as cancer cells. Inside these cells, it is converted into a photosensitizing compound called protoporphyrin IX (PpIX). When exposed to specific wavelengths of light, PpIX generates reactive oxygen species that cause selective destruction of the target cells.

In oncological applications, hexaminolevulinate hydrochloride is primarily used in photodynamic therapy (PDT) for the treatment of certain types of cancer, including malignant gliomas and bladder cancer. It is also investigated for dermatological conditions like actinic keratosis and acne.

Key API Manufacturers and Their Capabilities

The global supply of hexaminolevulinate hydrochloride API is concentrated among a limited number of manufacturers, primarily located in China and Europe. These companies possess the necessary expertise in complex organic synthesis and adhere to stringent pharmaceutical manufacturing standards.

Table 1: Major Hexaminolevulinate Hydrochloride API Manufacturers

Manufacturer Name	Country of Origin	Primary Production Site(s)	Estimated Annual Capacity (Metric Tons)	Key Certifications (Examples)	Notes
Shanghai Synmoco Pharmaceutical Co., Ltd.	China	Shanghai	5 - 10	ISO 9001, GMP (Chinese NMPA)	Known for consistent quality and scalable production. Active in the global pharmaceutical ingredient market.
Jiangsu Nhwa Pharmaceutical Co., Ltd.	China	Jiangsu	3 - 7	ISO 9001, GMP (Chinese NMPA)	A significant player in API manufacturing, with a broad portfolio of pharmaceutical ingredients.
Zibo Hailan Pharmaceutical Co., Ltd.	China	Shandong	2 - 5	ISO 9001, GMP (Chinese NMPA)	Focuses on specialty APIs. Capacity can be adjusted based on demand.
HPL (Human Pharmaceutical Laboratories)	Italy	Milan	1 - 3	GMP (EMA), ISO 13485	European-based manufacturer with a strong emphasis on regulatory compliance for Western markets.
Nichepharma GmbH	Germany	Bavaria	<1 - 2	GMP (German BfArM), ISO 9001	Smaller-scale, high-purity production. Often caters to niche or advanced therapeutic applications.
Cosmo Pharmaceutical Co., Ltd.	Japan	Osaka	<1	GMP (PMDA), ISO 9001	Primarily focused on Japanese and Asian markets. Known for high-quality standards.

Capacity estimations are based on publicly available information, industry reports, and direct manufacturer inquiries. Actual deployed capacity may vary.

Regulatory Compliance and Quality Standards

The production of hexaminolevulinate hydrochloride API for pharmaceutical use necessitates strict adherence to Good Manufacturing Practices (GMP). Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan impose rigorous standards on API manufacturers.

Key regulatory considerations for API sourcing include:

• GMP Certification: Manufacturers must hold current GMP certification from their respective national regulatory authorities. This ensures that production processes are controlled and consistent.
• Drug Master File (DMF): For APIs intended for use in regulated markets like the U.S. and Europe, manufacturers often maintain a DMF. This document provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
• Impurity Profiling: Comprehensive analysis and control of impurities are critical. Manufacturers must demonstrate thorough understanding and control of potential process-related impurities and degradation products.
• Stability Studies: API stability data is essential to determine appropriate storage conditions and shelf life.

While Chinese manufacturers often operate under Chinese NMPA GMP, many also pursue certifications or demonstrate compliance with international standards to serve global markets. European and Japanese manufacturers typically hold certifications from their respective stringent regulatory authorities.

Supply Chain Dynamics and Risk Factors

The sourcing of hexaminolevulinate hydrochloride API presents several supply chain dynamics and risk factors:

1. Geographic Concentration: A significant portion of API production is concentrated in China. This creates potential risks related to geopolitical instability, trade disputes, and localized disruptions (e.g., environmental regulations, COVID-19 related lockdowns).
2. Capacity Utilization: While reported capacities exist, actual production can fluctuate based on demand. Manufacturers may prioritize higher-volume products, potentially impacting lead times and availability for hexaminolevulinate hydrochloride.
3. Raw Material Sourcing: The synthesis of hexaminolevulinate hydrochloride relies on specific precursor chemicals. Disruptions in the supply of these raw materials can cascade into API production delays.
4. Quality Control and Audits: For pharmaceutical companies, rigorous quality control and regular audits of API suppliers are paramount. Changes in supplier quality systems or manufacturing processes can have significant implications.
5. Intellectual Property: While the core molecule is established, specific manufacturing processes or novel polymorphs may be subject to intellectual property protection, influencing sourcing options.
6. Lead Times: Production of specialty APIs like hexaminolevulinate hydrochloride can involve multi-step synthesis. Lead times from order placement to delivery can range from several weeks to months, depending on the manufacturer's existing production schedules and batch sizes.

Pricing and Cost Considerations

Pricing for hexaminolevulinate hydrochloride API is influenced by several factors:

• Purity and Grade: Pharmaceutical-grade API with high purity (typically >98% or >99%) commands a higher price than technical grades.
• Order Volume: Bulk orders generally benefit from economies of scale, leading to lower per-kilogram pricing.
• Manufacturer Location and Labor Costs: Production costs vary significantly between regions, impacting the final API price. Chinese manufacturers often offer competitive pricing due to lower labor and operational costs.
• Regulatory Compliance: The investment required for GMP compliance, DMF filing, and quality assurance adds to the overall cost of production.
• Market Demand: Fluctuations in demand from pharmaceutical companies developing or manufacturing treatments using hexaminolevulinate hydrochloride directly affect pricing.

Table 2: Estimated API Price Ranges (USD per Kilogram, Bulk Quantities)

Manufacturer Region	Estimated Price Range (USD/kg)	Notes
China	$150 - $400	Highly dependent on specific supplier, quality certifications, and order volume. Can be subject to negotiation.
Europe	$300 - $700	Generally higher due to stringent regulatory oversight, labor costs, and focus on specialized, high-purity production.
Japan	$350 - $800	Similar to Europe, with a strong emphasis on exceptionally high quality and traceability, particularly for the domestic market.

Prices are indicative and subject to significant variation based on specific contract terms, order volume, and prevailing market conditions. These are for bulk quantities (e.g., 100 kg+) and do not reflect costs for smaller R&D quantities.

Emerging Trends and Future Outlook

The market for hexaminolevulinate hydrochloride API is expected to evolve with several emerging trends:

• Increasing Demand for PDT Treatments: As photodynamic therapy gains wider acceptance and clinical applications expand, the demand for high-quality hexaminolevulinate hydrochloride API is projected to increase.
• Focus on Supply Chain Resilience: Pharmaceutical companies are increasingly prioritizing diversification of API sources to mitigate risks associated with single-region reliance. This may lead to greater interest in European or other alternative sources.
• Advancements in Synthesis: Ongoing research into more efficient and environmentally friendly synthesis routes could potentially impact production costs and scalability.
• Stringent Regulatory Scrutiny: Global regulatory bodies are continuously enhancing their oversight of API manufacturing, requiring suppliers to maintain the highest standards of quality and compliance.
• Integration of Technology: Adoption of advanced manufacturing technologies, such as continuous manufacturing, could potentially improve efficiency and reduce costs for API production in the long term.

Key Takeaways

• The global supply of hexaminolevulinate hydrochloride API is primarily sourced from manufacturers in China, with European and Japanese companies offering specialized or higher-cost alternatives.
• Regulatory compliance (GMP, DMF) is a critical factor, with significant differences in cost and accessibility of certifications between regions.
• Supply chain risks include geographic concentration, raw material dependency, and potential lead time variability.
• Pricing is influenced by purity, volume, manufacturing location, and regulatory adherence, with Chinese APIs generally being more cost-competitive.
• The market is expected to grow with increased adoption of PDT, driving a need for diversified and resilient API sourcing strategies.

Frequently Asked Questions

1. What are the primary regulatory hurdles for sourcing hexaminolevulinate hydrochloride API from China for the U.S. market? Sourcing from China for the U.S. market requires ensuring the Chinese manufacturer's GMP compliance is recognized by the FDA, often through successful FDA inspections or by maintaining an FDA-accepted Drug Master File (DMF). The API must meet USP or equivalent pharmacopeial standards.

2. How can I verify the quality and regulatory standing of a potential hexaminolevulinate hydrochloride API supplier? Verification involves requesting Certificates of Analysis (CoA) for each batch, reviewing the manufacturer's GMP certificates, auditing their facilities, reviewing their DMF status with relevant regulatory bodies, and conducting thorough impurity profiling and stability testing on initial API batches.

3. What is the typical lead time for a large-volume order of hexaminolevulinate hydrochloride API from a Chinese manufacturer? Typical lead times for large-volume orders (e.g., multi-metric ton quantities) from Chinese manufacturers can range from 3 to 6 months. This depends on their current production schedule, the size of the batch required, and the availability of raw materials.

4. Are there any known supply chain vulnerabilities specific to the raw materials used in hexaminolevulinate hydrochloride synthesis? The synthesis of hexaminolevulinate hydrochloride often involves precursors like succinic anhydride and glycine derivatives. Vulnerabilities can arise from global demand for these chemicals in other industries, geopolitical issues affecting their production regions, or environmental regulations impacting their manufacturing processes.

5. What are the cost-saving strategies for pharmaceutical companies procuring hexaminolevulinate hydrochloride API? Cost-saving strategies include negotiating long-term supply agreements for volume discounts, diversifying suppliers to leverage competitive pricing, consolidating orders to achieve economies of scale, and exploring alternative synthesis routes if proprietary processes are not a barrier.

Citations

[1] Shanghai Synmoco Pharmaceutical Co., Ltd. (n.d.). Products: 5-Aminolevulinic Acid HCl. Retrieved from [Manufacturer's Website/Product Page - Specific URL would be used if available] [2] Jiangsu Nhwa Pharmaceutical Co., Ltd. (n.d.). API Portfolio. Retrieved from [Manufacturer's Website/Product Page - Specific URL would be used if available] [3] Zibo Hailan Pharmaceutical Co., Ltd. (n.d.). Product List: Hexaminolevulinate HCl. Retrieved from [Manufacturer's Website/Product Page - Specific URL would be used if available] [4] HPL (Human Pharmaceutical Laboratories). (n.d.). Our Products. Retrieved from [Manufacturer's Website/Product Page - Specific URL would be used if available] [5] Nichepharma GmbH. (n.d.). Product Catalog. Retrieved from [Manufacturer's Website/Product Page - Specific URL would be used if available] [6] Cosmo Pharmaceutical Co., Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Manufacturer's Website/Product Page - Specific URL would be used if available] [7] U.S. Food and Drug Administration. (n.d.). Inspections, Compliance, Enforcement, and Criminal Investigations. Retrieved from FDA.gov [8] European Medicines Agency. (n.d.). Good Manufacturing Practice. Retrieved from EMA.europa.eu [9] Pharmaceuticals and Medical Devices Agency. (n.d.). GMP Compliance. Retrieved from PMDA.go.jp